Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas

Molecular Cancer Therapeutics

Volumn 11, Issue 2, 2012, Pages 492-502

  Zajchowski, Deborah A ^a   Karlan, Beth Y ^b   Shawver, Laura K ^a  

^a Clearity Foundation   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIESTROGEN; AROMATASE INHIBITOR; BIOLOGICAL MARKER; BREAST CANCER RESISTANCE PROTEIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ESTROGEN RECEPTOR; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; OSTEONECTIN; PLATINUM; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; TAXANE DERIVATIVE; THYMIDYLATE SYNTHASE; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN;

ADVANCED CANCER; ARTICLE; CANCER PATIENT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT CANCER; UNIVARIATE ANALYSIS;

ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; CYSTADENOCARCINOMA, SEROUS; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84856875047     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0746     Document Type: Article

References (24)

1. Shin HR BF, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2. Cancer Incidence and Mortality Worldwide: IARC Cancer Base [Internet]. 2008 [cited 2011 9/15/2011]; Available from: http://globocan.iarc.fr
2. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol 1996;23:40-7. (Pubitemid 26391379)
3. ACS. Cancer facts and figures 2011. Atlanta: American Cancer Society; 2011.
4. Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 2005;11:6422-30. (Pubitemid 41338978)
5. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008;14:5198-208.
6. TCGA. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
7. Hoefnagel LD, van de Vijver MJ, van Slooten HJ, Wesseling P, Wesseling J, Westenend PJ, et al. Receptor conversion in distant breast cancer metastases. Breast Cancer Res 2010;12: R75.
8. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 2004;101:9393-8. (Pubitemid 38812885)
9. Naniwa J, Kigawa J, Kanamori Y, Itamochi H, Oishi T, Shimada M, et al. Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer. Int J Gynecol Cancer 2007;17: 76-82. (Pubitemid 46213973)
10. Rutledge ML, Robey-Cafferty SS, Silva EG, Bruner JM. Monoclonal antibody C219 detection of the multidrug-resistant protein P-glycoprotein in routinely processed tissues: a study of 36 cases of ovarian carcinoma. Mod Pathol 1990;3:298-301.
11. van der Zee AG, Hollema H, Suurmeijer AJ, Krans M, Sluiter WJ, Willemse PH, et al. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 1995;13:70-8.
12. Penson RT, Oliva E, Skates SJ, Glyptis T, Fuller AF Jr, Goodman A, et al. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol 2004;93:98-106. (Pubitemid 38429555)
13. Wrigley E, Verspaget HW, Jayson GC, McGown AT. Metallothionein expression in epithelial ovarian cancer: effect of chemotherapy and prognostic significance. J Cancer Res Clin Oncol 2000;126:717-21.
14. Surowiak P, Materna V, Kaplenko I, Spaczynski M, Dietel M, Lage H, et al. Topoisomerase 1A, HER/2neu and Ki67 expression in paired primary and relapse ovarian cancer tissue samples. Histol Histopathol 2006;21:713-20. (Pubitemid 44082713)
15. Benjamini Y, Hochberg J. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc B (Methodological) 1995;57:289-300.
16. Gossage L, Madhusudan S. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 2007; 33:565-77. (Pubitemid 47355341)
17. Materna V, Pleger J, Hoffmann U, Lage H. RNA expression of MDR1/ P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol 2004;94:152-60. (Pubitemid 38950512)
18. McGown AT, Murphy D, Swindell R, Crowther D, Fox BW. Correlation of drug resistance-associated parameters in ovarian tumor biopsies. Int J Gynecol Cancer 1994;4:241-9.
19. Hille S, Rein DT, Riffelmann M, Neumann R, Sartorius J, Pfutzner A, et al. Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer. Anticancer Drugs 2006;17:1041-4. (Pubitemid 44454781)
20. Kobayashi H, Sugihara K, Uetake H, Higuchi T, Yasuno M, Enomoto M, et al. Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis. Int J Oncol 2008;33:1257-62.
21. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991;9:389-93.
22. Lancaster JM, Dressman HK, Clarke JP, Sayer RA, Martino MA, Cragun JM, et al. Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. Int J Gynecol Cancer 2006;16:1733-45. (Pubitemid 44470029)
23. Khalique L, Ayhan A, Whittaker JC, Singh N, Jacobs IJ, Gayther SA, et al. The clonal evolution of metastases from primary serous epithelial ovarian cancers. Int J Cancer 2009;124:1579-86.
24. Reynolds C, Obasaju C, Schell MJ, Li X, Zheng Z, Boulware D, et al. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 2009;27:5808-15.